Τίτλος:
The Co-existence of NASH and chronic kidney disease boosts cardiovascular risk: Are there any common therapeutic options?
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease. NAFLD may evolve to non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD) mortality. There is no generally accepted effective treatment for NAFLD/NASH. Chronic kidney disease (CKD) is relatively common and might co-exist with NAFLD/NASH, aggravate one another, and increase CVD risk. Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin, ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those on the same statins but without liver disease and CVD-related events are reduced by atorvastatin for patients with all stages of CKD. The new anti-diabetic medication classes, the sodium-glucose co-transporter-2 inhibitors (SGLT2i) and the glucagon like peptide receptor agonists (GLP1 RA) for patients with NAFLD/NASH, CKD and T2DM are useful because they ameliorate NAFLD/NASH, delay the evolution of CKD, and substantially reduce CVD and all-cause mortality. Thus, the common use of high potency statins, renin-angiotensin-aldosterone system inhibitors, and the newer anti-diabetic agents increase compliance and can substantially reduce CVD risk and the rate of liver and kidney adverse events, improving quality of life and survival. © 2018 Bentham Science Publishers.
Συγγραφείς:
Papademetriou, M.
Athyros, V.G.
Geladari, E.
Doumas, M.
Tsioufis, C.
Papademetriou, V.
Περιοδικό:
Current Vascular Pharmacology
Εκδότης:
Bentham Science Publishers B.V.
Λέξεις-κλειδιά:
aldosterone; atorvastatin; empagliflozin; glucagon like peptide receptor; liraglutide; rosuvastatin; sodium glucose cotransporter 2; statin (protein); antidiabetic agent; antihypertensive agent; hydroxymethylglutaryl coenzyme A reductase inhibitor, cardiovascular disease; cardiovascular mortality; cardiovascular risk; cerebrovascular accident; chronic kidney failure; chronic liver disease; heart infarction; histology; human; insulin resistance; mortality; nonalcoholic fatty liver; oxidative stress; pathophysiology; peripheral occlusive artery disease; quality of life; renin angiotensin aldosterone system; Review; steatosis; transient ischemic attack; treatment outcome; animal; cardiovascular disease; chronic kidney failure; comorbidity; drug effect; nonalcoholic fatty liver; prevalence; risk factor; treatment outcome, Animals; Antihypertensive Agents; Cardiovascular Diseases; Comorbidity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Prevalence; Renal Insufficiency, Chronic; Renin-Angiotensin System; Risk Factors; Treatment Outcome
DOI:
10.2174/1570161115666170621081638
